Bank of America Securities Sticks to Their Hold Rating for Zoetis (ZTS)

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Hold rating on Zoetis, with a price target of $140.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ryskin covers the Healthcare sector, focusing on stocks such as Zoetis, Bruker, and Idexx Laboratories. According to TipRanks, Ryskin has an average return of 1.1% and a 47.33% success rate on recommended stocks.

In addition to Bank of America Securities, Zoetis also received a Hold from TipRanks – Google’s Google Drug Manufacturers – Specialty and Generic in a report issued on March 31. However, yesterday, Argus Research reiterated a Buy rating on Zoetis (NYSE: ZTS).

Based on Zoetis’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.39 billion and a net profit of $603 million. In comparison, last year the company earned a revenue of $2.32 billion and had a net profit of $581 million

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year. Most recently, in February 2026, Kristin Peck, the CEO of ZTS sold 20,000.00 shares for a total of $2,540,864.00.